MX2015012631A - Polipeptidos de leptina de canino modificados. - Google Patents

Polipeptidos de leptina de canino modificados.

Info

Publication number
MX2015012631A
MX2015012631A MX2015012631A MX2015012631A MX2015012631A MX 2015012631 A MX2015012631 A MX 2015012631A MX 2015012631 A MX2015012631 A MX 2015012631A MX 2015012631 A MX2015012631 A MX 2015012631A MX 2015012631 A MX2015012631 A MX 2015012631A
Authority
MX
Mexico
Prior art keywords
modified canine
leptin polypeptides
canine leptin
polypeptides
modified
Prior art date
Application number
MX2015012631A
Other languages
English (en)
Inventor
Michael Bledsoe
Peter Connor Canning
Michael Deguzman
Nick Lnudsen
Ianina Valenta
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2015012631A publication Critical patent/MX2015012631A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat

Abstract

Los polipéptidos de leptina de canino modificados y formulaciones y usos de los mismos, son provistos incluyendo polipéptidos de leptina de canino modificados con polietilenglicol (PEG), en donde la porción de PEG es unida covalentemente a un residuo de para-acetil-fenilalanina (pAF) del polipéptido, y composiciones y métodos relacionados útiles para tratar obesidad den animales de compañía y otros desórdenes relacionados con leptina.
MX2015012631A 2013-03-13 2014-03-12 Polipeptidos de leptina de canino modificados. MX2015012631A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361779337P 2013-03-13 2013-03-13
PCT/US2014/024706 WO2014165189A2 (en) 2013-03-13 2014-03-12 Modified canine leptin polypeptides

Publications (1)

Publication Number Publication Date
MX2015012631A true MX2015012631A (es) 2016-06-21

Family

ID=50680127

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012631A MX2015012631A (es) 2013-03-13 2014-03-12 Polipeptidos de leptina de canino modificados.

Country Status (16)

Country Link
US (1) US10105447B2 (es)
EP (1) EP2970424B1 (es)
JP (2) JP6423852B2 (es)
KR (1) KR20150126035A (es)
CN (1) CN105121461A (es)
AU (1) AU2014248617B2 (es)
BR (1) BR112015021364A2 (es)
CA (1) CA2901928C (es)
DK (1) DK2970424T3 (es)
ES (1) ES2642624T3 (es)
HU (1) HUE033443T2 (es)
IL (1) IL240964B (es)
MX (1) MX2015012631A (es)
PL (1) PL2970424T3 (es)
PT (1) PT2970424T (es)
WO (1) WO2014165189A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4087612A1 (en) * 2020-01-08 2022-11-16 Bristol-Myers Squibb Company Fgf-21 conjugate formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997032022A2 (en) 1996-03-01 1997-09-04 Amgen Inc. Canine ob protein compositions and methods
JP2000279171A (ja) 1999-03-30 2000-10-10 Morinaga & Co Ltd イヌ肥満遺伝子、その遺伝子産物とその製造法及び測定試薬と測定法
CA2388417A1 (en) * 1999-09-22 2001-03-29 Genset Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases
DE60327369D1 (de) 2002-10-16 2009-06-04 Scripps Research Inst Stellenspezifischer einbau von ketoaminosäuren in proteine
CN101113175A (zh) * 2007-04-28 2008-01-30 中国科学院西北高原生物研究所 鼠兔家族瘦素蛋白及其cDNA序列
CN101939443B (zh) * 2008-02-08 2014-01-29 Ambrx公司 经修饰瘦素多肽和其用途
JP5413766B2 (ja) 2008-03-10 2014-02-12 株式会社シバヤギ レプチン測定方法
WO2011014890A1 (en) 2009-07-31 2011-02-03 Bayer Healthcare Llc Modified factor ix polypeptides and uses thereof

Also Published As

Publication number Publication date
AU2014248617B2 (en) 2016-05-19
CA2901928C (en) 2017-10-10
JP6434071B2 (ja) 2018-12-05
WO2014165189A2 (en) 2014-10-09
IL240964B (en) 2019-07-31
JP6423852B2 (ja) 2018-11-14
DK2970424T3 (en) 2017-07-31
HUE033443T2 (en) 2017-11-28
BR112015021364A2 (pt) 2017-10-10
EP2970424A2 (en) 2016-01-20
JP2016514144A (ja) 2016-05-19
ES2642624T3 (es) 2017-11-17
JP2017110024A (ja) 2017-06-22
US20150366983A1 (en) 2015-12-24
EP2970424B1 (en) 2017-06-21
CN105121461A (zh) 2015-12-02
WO2014165189A3 (en) 2014-11-27
IL240964A0 (en) 2015-11-30
PT2970424T (pt) 2017-08-25
US10105447B2 (en) 2018-10-23
CA2901928A1 (en) 2014-10-09
PL2970424T3 (pl) 2017-11-30
AU2014248617A1 (en) 2015-09-17
KR20150126035A (ko) 2015-11-10

Similar Documents

Publication Publication Date Title
CY1122898T1 (el) Απεκκριση πολυπεπτιδιων που περιεχουν αιμη
WO2014197871A3 (en) Antibody-drug conjugates, compositions and methods of use
TN2017000246A1 (en) Anti-c10orf54 antibodies and uses thereof
IL240673B (en) Synthesis and Composition of Conjugated Amino Acid Binding Groups for Compounds Used for Targeted Imaging of Tumors
MX2016016515A (es) Derivados de auristatina y conjugados de los mismos.
IL264345A (en) Immunogenic/medical glycan preparations and their uses
TW201614041A (en) Compositions for electronic devices
DK3570879T3 (da) Immunogene sammensætninger til anvendelse i pneumokokvacciner
PH12018500315A1 (en) Fumagillol heterocyclic compounds and methods of making and using same
UA111098C2 (uk) Проліки адреномедуліну на основі поліетиленгліколю і їх застосування
PH12017500836A1 (en) Transdermal formulations
MX2014008706A (es) Compuestos tricíclicos de sulfonamida y métodos para elaborarlos y usarlos.
IL251120B (en) Immunogenic/therapeutic glycoside preparations and their uses
MX2017002584A (es) Composicion y producto medicinal para reducir peso corporal y grasa corporal, y uso del producto.
EA201590491A1 (ru) Иммуногенная композиция
CL2014003325A1 (es) Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimer
MX2016009241A (es) Metodos para reducir el mal olor y las bacterias.
HRP20190344T1 (hr) Farmaceutski sastavi i uporabe usmjerene na lizosomske poremećaje skladištenja
SI3157522T1 (sl) Muskarinski antagonisti in njihove kombinacije za zdravljenje bolezni dihalne poti pri konjih
CL2016002839A1 (es) Derivados de carboxamida
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
GB201421373D0 (en) Modified amine curing agents, their preparation and use in curable compositions
SG11201704500VA (en) Antibody binding to neuropilin 1 and use thereof
FR3002454B1 (fr) Composition immunogene sous forme d'emulsion
TR201819263T4 (tr) Nörolojik hastalıkların tedavisi için pantotenat türevleri.